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Background: Dyslipidemia management situation in Chinese patients with high risk and very high risk has been
demonstrated very low, despite the wide use of statins. The effects and safety of the combined treatment of
ezetimibe (EZ) and statins in Chinese patients with acute coronary syndrome (ACS) and type 2 diabetes mellitus
(T2DM) remain unknown.
Methods: Chinese Patients with ACS and T2DM were divided into the statins group (n = 40) and the
combination group of EZ and statins (n = 44). In order to evaluate the clinical effects on lipids-lowering,
systemic inflammation response and clinical safety, the follow-up of all patients was carried out at day 7th and
30th after treatment.
Results: The level of low-density lipoprotein cholesterol (LDL-C) in combination group and statins group was
1.87 ± 0.42 and 2.18 ± 0.58 mmol/L at day 7th, 1.51 ± 0.29 and 1.94 ± 0.49 mmol/L at day 30th, respectively.
The control rates of LDL-C level in the combination group and the statins group were 77% and 45% at day 30th,
respectively. There was no significant improvement on high-density lipoprotein cholesterol (HDL-C) level during
follow-up. The triglyceride (TG) levels were significantly reduced in both groups, while no obvious difference was
observed between two groups. No significant difference on serum high-sensitivity C-reactive protein (hs-CRP)
level between two groups was observed. Moreover, we did not observe any significant correlation between
serum lipids levels and serum hs-CRP level during follow-up. The liver dysfunction and muscle related side effects
(MRSE), creatine kinase (CK) and myopathy were not observed in both groups.
Conclusion: Our study demonstrated that it is feasible to initiate combination therapy during acute phase for
Chinese patients with ACS and T2DM, which can bring more significant effect on LDL-C-lowering and improve
the control rate of LDL-C level with good safety.
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Diabetes mellitus (DM) has been demonstrated as cor-
onary heart disease (CHD) risk equivalent and is associ-
ated with 2- to 4-fold increase in the risk of CHD [1].
The risk of acute coronary events or cardiovascular
death events of diabetic patients within 10 years is
equivalent to the patients with old myocardial infarction.
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unless otherwise stated.much higher cardiovascular mortality (45%) than non
diabetes with prior myocardial infarction (MI) (18.8%) [2].
Thus, the risk of cardiovascular events is very high in the
acute coronary syndrome (ACS) patients complicated with
type 2 diabetes mellitus (T2DM). Dyslipidemia, especially
increased low-density lipoprotein cholesterol (LDL-C)
level is a pathogenic risk factor for CHD. Meta-analysis
showed that the 1 mmol/L reduction in LDL-C bring 23%
reduction in cardiovascular disease (CVD) within 5 years
[3]. The 2014 AHA/ACC guideline for the management of
patients with non-ST-elevation acute coronary syndrome
(NSTE-ACS) emphasized that NSTE-ACS patients couldis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Li et al. Lipids in Health and Disease  (2015) 14:10 Page 2 of 7benefit more from high-intensity statins therapy in redu-
cing the rate of recurrent MI, CHD mortality and the need
for revascularization and stroke [4]. Recently, the DYSIS-
China Survey of dyslipidemia management situation in pa-
tients treated with lipid-lowering agents showed that the
LDL-C control rate in high risk and very high risk popula-
tion were 54.8% and 39.7%, respectively [5]. Clinical re-
search revealed that the doubling dosage of statins can
only bring 6% incremental reduction of LDL-C level, and
probably increased the risk of DM and worsen the gly-
cemic control in diabetic patients [6]. Moreover, HPS2-
THRIVE study demonstrated that Chinese individuals have
much higher risk of myopathy with Simvastatin 40 mg
alone (0.13%/year vs. 0.04%/year, p = 0.001) or combined
with niacin (0.53%/year vs. 0.03%/year), compared with
those of European [7]. Therefore, most of Chinese patients
are not tolerable to the intensive dosage of statins as guide-
line suggested [4]. We need to explore an appropriate
cholesterol-lowering therapy for high risk patients in
China. Ezetimibe (EZ) inhibits cholesterol absorption from
the small intestine by selectively inhibiting the cholesterol
transporter, Niemann-Pick C1 like1 (NPC1L1) protein
which result in the decreased cholesterol delivery to liver,
thus lower the plasma cholesterol level [8]. Statins com-
bined with EZ can further decrease LDL-C levels by 6% ~
25% in hypercholesterolemia patients who cannot achieve
the recommended LDL-C level with statins monotherapy
and significantly improve the control rate of LDL-C level
[9]. Recent report showed that EZ 10 mg/d combined with
low dose pravastatin 10 mg/d can lead to the improvement
in insulin resistance (IR) compared with high dose prava-
statin 40 mg/d in CHD patients with hyperlipidemia [10],
which probably related to the EZ inhibition on the reactive
oxygen species production and insulin-induced endoplas-
mic reticulum stress [11]. Thereby, the patients of meta-
bolic syndrome and T2DM may get additional benefit
from the combination therapy of EZ and statins. Neverthe-
less, the evidence of EZ combined with statins is limited in
Chinese CVD with very high risk population. The present
study aims to observe the efficacy and safety of the com-
bined lipid-lowering therapy in Chinese patients with ACS
and T2DM during acute phase.Materials and methods
Patients
Patients admitted for ACS and T2DM in the Department
of Cardiology of Shengjing hospital from December 2011
to December 2012 were enrolled. Patients presented with
an ACS including ST-elevation myocardial infarction
(STEMI) in 24 h or non-ST-elevation myocardial infarc-
tion (NSTEMI) in 48 h and high-risk unstable angina
(UA) in 48 h were eligible for inclusion. Hospital ethical
boards approved the study.Exclusion criteria included the chronic inflammatory
disease or the history of acute infection within 1 month;
connective tissue disease and autoimmune disease which
diagnosed clearly; the tumors and aneurysm; the history
of operation or injury within 3 months; severe congest-
ive heart failure (New York Heart Association class
III-IV) or cardiogenic shock; malignant arrhythmia (atrio-
ventricular block aboveIIgrade, ventricular tachycardia,
ventricular fibrillation); received probucol or other lipid-
lowering treatment such as nicotinic acid, bile-acid se-
questrating, fish oil and garlic products within 8 weeks;
impaired hepatic function; the estimated glomerular filtra-
tion rate (eGFR) < 30 ml/min; 3 times of the upper limit of
normal (ULN) in the creatine kinase (CK) level and no re-
lation with myocardial infarction; thyroid dysfunction. The
study was approved by the Ethics Committee of Shengjing
Hospital of China Medical University (Shenyang, China).
All procedures were performed in accordance with
ethical standards. All subjects participated in the study
after making signed informed consents.
Study design
In this prospective, observational and real word study,
eligible patients received the statins (rosuvastain 10 mg/d,
atorvastatin 20 mg/d simvastatin 20 mg/d and pravastatin
20 mg/d) or combination of EZ 10 mg/d with the above
dosage of statins. In addition, all patients were treated
with 100 mg/d of aspirin, 75 mg/d of clopidogrel and in
appropriate individuals with the treatment of β-blocker,
angiotensin concerting enzyme inhibitor or angiotensin
receptor blocker, percutaneous transluminal coronary
angioplasty and coronary stent implantation.
Laboratory assays
The plasma lipids and serum hs-CRP were measured from
fasting blood samples at admission, at day 7th and 30th
after treatment. The primary endpoints include LDL-C
level, its control rate and the safety; the secondary end-
point is serum hs-CRP level. The plasma total cholesterol
(TC) and triglyceride (TG) were tested by oxidase
methods, the plasma high-density lipoprotein cholesterol
(HDL-C) was measured by chemical modified enzyme
method, the plasma LDL-C was tested by selective dissol-
ution method, and the serum hs-CRP was measured by
immune transmission turbidimetric method. The baseline
levels of CK, CK-MB, and aspartate aminotransferase
(AST) came from the lowest levels within 3 days after ad-
mission, considering that the increase of CK, isoenzyme of
CK-MB and AST due to myocardial infarction probably
interfere with analysis of myopathy and liver dysfunction.
Safety assessment
Safety evaluation based on patient report, investigator
observation and laboratory test during the follow-up.






Male/female 24/20 24/16 0.614
UA/NSTEMI/STEMI 21/14/9 24/10/6 0.528
ROS/ATOR/SIM/PRA 25/15/2/2 29/8/2/1 0.962
Age (year) 62 ± 1.5 64± 1.5 0.514
BMI 25.1± 0.15 24.7± 0.19 0.136
smoking/non-smoking 18/26 16/24 0.932
TC (mmol/L) 4.70± 0.17 4.43± 0.15 0.252
TG (mmol/L) 1.93± 0.17 2.02± 0.19 0.459
HDL-C (mmol/L) 1.00± 0.03 1.00± 0.04 0.966
LDL-C (mmol/L) 3.07± 0.14 2.70± 0.13 0.053
hs-CRP (mg/L) 4.55± 0.70 4.15±0.80 0.711
ALT (IU/L) 28± 3.5 30± 2.9 0.726
AST (IU/L) 61± 16 52±11 0.658
TBIL (Umol/L) 10.2± 0.68 9.7±0.66 0.724
Cr (μmol/L) 77.5± 4.52 78.6±5.59 0.871
FBG (mmol/L) 7.66± 0.39 8.27±0.62 0.092
HbA1C (%) 7.4±0.32 7.9±0.28 0.187
CK (U/L) 101±29 117±24 0.433
CK-MB (U/L) 23±7 19±6 0.547
TnI (μg/L) 16.17±4.85 12.14±4.52 0.545
Data are presented as mean ±SE. P value less than 0.05 for significant
difference between two groups at baseline.
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ferase (ALT) level that was more than 3 times the ULN
or the AST level that was more than 5 times the ULN
were considered elevated. Muscle related side effects
(MRSE) were defined as CK greater than 5 times the
ULN with or without myopathy symptoms.
Statistical analysis
Data are performed with SPSS 19.0 software and pre-
sented as mean ± SE. The paired t test is used to com-
pare the baseline and posttreatment at 7th and 30th in
each group. Independent-samples t test is used for com-
parison between two treatment groups. χ2 analysis is
used to examine the categorical data between treatment
groups. P values less than 0.05 are regarded as statisti-
cally difference. The relations between lipids levels and
serum hs-CRP are tested by bivariate analysis.
Results
Baseline characteristics
Of the 157 patients enrolled for the study, 84 patients
were matched the inclusion criteria without exclusion
criteria. All the 84 patients completed the study. Among
these patients, 40 patients received the statins mono-
therapy (29 on rosuvastatin 10 mg/d, 8 on atorvastatin
20 mg/d, 2 on simvastatin 20 mg/d, 1 on pravastatin
20 mg/d) and 44 patients received the 10 mg/d EZ com-
bined with statins (25 on rosuvastatin 10 mg/d, 15 on
atorvastatin 20 mg/d, 2 on simvastatin 20 mg/d, 2 on
pravastatin 20 mg/d). The treatment groups were well
matched with regard to the baseline characteristics. The
average age was 63 years and women accounted for 57%.
Of the patients who were received treatment, 54% UA,
28% NSTEMI and 18% STEMI (Table 1).
Levels of the lipids
In the present study, compared with statins group, the
greater reduction of LDL-C level in combination group
was observed at day 7th (39% vs. 18.5%, P = 0.007) and
this effectiveness continued through-out the 30 day
treatment period (50% vs. 29%, P < 0.001). According to
the 2011 ESC/EAS Guidelines for the management of
dyslipidemia, the optimal level or relative reduction ratio
of the LDL-C level should be less than 1.8 mmol/L or
greater than 50% reduction, the greater proportion of
patients in the combination group achieved the LDL-C
goal attainment, compared with the statins group (77%
vs. 45%, P = 0.002) (Figure 1A).
TC levels in two groups were obviously reduced. The TC
levels in combination group and statins group were reduced
by 42% and 25% at day 30th, respectively (Figure 1B).
TG levels in the combination group and statins
group were significantly reduced by 20% (p = 0.000)
and 22% (p = 0.000) at day 30th, respectively. However,no significant difference was observed between two
groups (Figure 1C).
Moreover, HDL-C levels in both groups did not show
any significant elevation during the 30 days follow-up
(Figure 1D).
Hs-CRP level
In addition to the lipid-lowering effects, we also observed
that serum hs-CRP levels were obviously decreased in the
combination group by 47% (P = 0.000) and statins group
by 42% (P = 0.001) at day 30th, compared with the baseline
levels. Nevertheless, there was no significant difference
on hs-CRP reduction between two groups (P = 0.365)
(Figure 2).
Furthermore, we tested the relationship between serum
hs-CRP and plasma lipids. Bivariate analysis showed that
there was no significant correlation between serum
hs-CRP level and plasma lipids levels (Table 2).
Safety evaluation
Treatment-related side effects were not observed in this
study. No patients showed an increasement in ALT greater
than 3 times the ULN or AST greater than 5 times the
ULN. No case of hepatitis or jaundice was observed. No
Figure 1 Plasma lipids levels in both groups during follow-up. ACS patients with T2DM divided into two groups, the combination group who
received EZ 10 mg/d with standard dose of statins (n=44) and statins group who received standard dose of statins (n=40). Plasma lipids levels were
tested at baseline, 7th day and 30th day after treatment. (A) LDL-C levels and control rate of LDL-C. *Indicate the percentage control rate of LDL-C level,
P=0.002. (B, C, D) TC, TG, HDL-C levels. *p=0.000 versus TG level at baseline in combination group.#p=0.000 versus TG level at baseline in statins group.
Data are shown as mean ± SE. Independent t test was to compare the significant difference of treatment groups. Data expressed as as mean ± SE.
Figure 2 Inflammation markers of both groups during follow-up.
The anti-inflammatory effects of EZ combined with statins and statins
monotherapy were evaluated during follow-up. Hs-CRP level was
measured at baseline, 7th day and 30th day. Paired t test was used
to compare significance of pre and posttreatment. Independent t
test was used to examine the difference between the treatment
groups. Data are expressed as mean ± SE.
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tested with greater than 5 times elevations of CK levels
(Figure 3).
Discussion
CVD has been demonstrated as one of the most important
life-threatening disease in Chinese population [12,13].
Clinical researches verified that the intensive treatment of
LDL-C reduced cardiovascular events in patients after MI
[14]. The 17% reduction of clinical events was obviously at
30th with intensive lipid-lowering therapy after ACS [15].
Previous study reported that the combination therapy of
EZ/40 mg/d Simvastatin produced 52% reduction of LDL-C
level in ACS patients [16]. In the present study, we provided
the evidence that the treatment of EZ combined with mod-
erate statins can bring 50% reduction of the LDL-C level at
30th in Chinese ACS patients with T2DM. The results dem-
onstrate that the combination group produced more LDL-C
reduction during acute phase for Chinese ACS patients with
T2DM. The greater reduction of LDL-C level was observed
in the combination group compared with statins group
(39% VS. 18.5%, p = 0.007) at day 7th after treatment. LDL-C
level was reduced by 50% in the combination therapy group
at day 30th. An additional 21% reduction was observed in
Table 2 Correlation between hs-CRP and lipids levels
TC LDL-C TG HDL-C
Hs-CRP R -0.242 -0.135 -0.291 0.210
P 0.133 0.068 0.140 0.193
Data are presented as mean ±SE. P value are less than 0.05 for significant
correlation.
Li et al. Lipids in Health and Disease  (2015) 14:10 Page 5 of 7patients received combination therapy at day 30th. Accord-
ing to the 2011 ESC/EAS guideline for the management of
dyslipidemia for patients with very high risk, the target level
of LDL-C should be less than 1.8 mmol/L or reduced by
50%, our study show that there are 77% patients in the com-
bination group achieved the recommended LDL-C goal,
compared with 45% patients in statins group. This study
demonstrated that the combination therapy significantly im-
prove the control rate of LDL-C level during acute phase of
ACS in Chinese patients with T2DM. Therefore, adding EZ
to moderate statins is more effective strategy to get signifi-
cant additional LDL-C-lowering and make more Chinese
patients to achieve LDL-C goal. Recent study reported that
the early reduction of LDL-C level was associated with the
reduced cardiovascular events such as recurrent ischemic
events and death in ACS patients in the 16 weeks [17]. The
present study indicates that stains combined with EZ bring
more Chinese ACS patients with T2DM achieve the target
LDL-C the goal in early stage, more patients will benefit
from lower LDL-C level eventually. Recently, the IMPROVE
IT trial demonstrated that the LDL-C level was significantly
decreased in EZ/Simvastatin group compared with the sim-
vastatin group in the 30 days. In addition, LDL-C lowering
effect in combination therapy continued through-out at least
2.5 years follow-up with good safety and significantly re-
duced the incidences of CVD morality, MI and stroke.
The levels of TG were decreased by 20% and 22% in
combination group and statins group at day 30th, re-
spectively, but no significant difference was observed be-
tween two groups. However, previous study showed that
TG level was decreased significantly in the EZ combined
with statins, compared with statins monotherapy [18]. In
our study, it is hard to further reduce TG level becauseFigure 3 Safety evaluation during follow-up after treatment. Liver dys
admission and at 30th day. (A, B, C) liver dysfunction marker ALT, TBIL and
observed in combination group and statins group after treatment. Data prethe baseline TG level approached to normal level. Our
data indicates that the further reduction of TG level pro-
duced by EZ is limited when TG level is close to normal.
No improvement on the HDL-C levels were observed
in both groups, supporting that either statins or statins
combined with EZ were not potent enough to improve
HDL-C level in Chinese ACS with T2DM patients.
Previous studies show that the combination of EZ and
statins provided greater reduction on hs-CRP compared
with statins monotherapy for 12 weeks in hypercholes-
terolemia patients [19,20]. We observed that the levels
of serum hs-CRP were significantly decreased in both
groups at day 30th, compared with those at baseline.
Nevertheless, there was no significant difference between
two groups (47% and 42%, P = 0.365) at 30th day. Statins
proportion in each group may account for the difference.
There were much more rosuvastatin (73% vs. 57%) and
less atorvastatin (20% vs. 34%) in statins group, com-
pared with those in the combination group. Moreover, the
reduction of hs-CRP levels in each group might be ex-
plained by acute inflammation regression after acute stage
of ACS and may not be related to the statins or statins
combined with EZ. Therefore, based on the present evi-
dence, we cannot overemphasize the anti-inflammatory ef-
fects of either statins or EZ [21].
The recent study showed that EZ can improve the
IR in the metabolic syndrome with elevated LDL-C
(>120 mg/dl) patients in the EZ group [22]. Nonetheless,
here we did not observe the effect of EZ on IR in Chin-
ese ACS with T2DM patients. If possible, we would like
to further evaluate the effectiveness of EZ on IR in Chin-
ese patients in future study.
Furthermore, we evaluated the safety of combination
therapy in the early stage of ACS. No significant eleva-
tions of liver enzymes, CK or myopathy were observed
in both groups. These data support that the combination
therapy of EZ and statins has similar safety as statins
monotherapy in Chinese ACS patients with T2DM.
The limitation of our study is small sample size. It is
worth to further evaluate the clinical effect of thefunction and MRSE marker were from lowest levels within 3 days after
MRSE marker CK at 0th and 30th after treatment. Side effects was not
sented as mean ± SE.
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and T2DM with enough longer follow-up.Conclusions
In Chinese patients with ACS and T2DM, the combin-
ation therapy of EZ and statins at dose used in stable
CHD can bring extra LDL-C-lowering effect and improve
the control rate of LDL-C level compared with the statins
monotherapy. Furthermore, patients with ACS and T2DM
should benefit from the early reduction of LDL-C level in
combination therapy with safety profile compared with
statins group. It is necessary to further investigate the ef-
fects and safety of EZ combined with moderate statins in
larger Chinese population with ACS and T2DM for longer
follow-up, expecting the clinical trial could provide more
strong evidence for the application of the EZ and statins
in Chinese ACS patients with T2DM.Consent
Written informed consent was obtained from the patient
for the publication of this report and any accompanying
images.
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